Skip to main content
47°
Light Rain
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Geovax Labs
(NQ:
GOVX
)
1.850
UNCHANGED
Streaming Delayed Price
Updated: 3:45 PM EDT, Mar 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
1.850
Bid (Size)
1.800 (1)
Ask (Size)
2.050 (5)
Prev. Close
1.850
Today's Range
1.850 - 1.850
52wk Range
0.2500 - 4.330
Shares Outstanding
2,172,309
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
GeoVax to Present at the 36th Annual Roth Conference
March 12, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
GeoVax Labs, Inc. (NASDAQ: GOVX) Featured in Coverage of the 36th Annual Roth Conference
March 08, 2024
Via
Investor Brand Network
Exposures
COVID-19
Performance
YTD
+400.00%
+400.00%
1 Month
-21.61%
-21.61%
3 Month
+395.98%
+395.98%
6 Month
+262.18%
+262.18%
1 Year
+197.81%
+197.81%
More News
Read More
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
March 06, 2024
Via
NewMediaWire
Geovax Labs: Q4 Earnings Insights
February 29, 2024
Via
Benzinga
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
February 29, 2024
Via
NewMediaWire
Exposures
COVID-19
Earnings Scheduled For February 29, 2024
February 29, 2024
Via
Benzinga
Earnings Outlook For Geovax Labs
February 28, 2024
Via
Benzinga
InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
February 23, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
February 22, 2024
Via
NewMediaWire
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
February 22, 2024
Via
TheNewswire.com
GeoVax to Present at the 2024 BIO CEO & Investor Conference
February 19, 2024
Via
NewMediaWire
GeoVax to Present at the 2024 BIO CEO & Investor Conference
February 19, 2024
Via
TheNewswire.com
GeoVax Announces Multiple Patent Issuances and Allowances
February 13, 2024
Via
NewMediaWire
Topics
Intellectual Property
Exposures
Intellectual Property
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
February 06, 2024
Via
NewMediaWire
Exposures
COVID-19
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
February 06, 2024
Via
TheNewswire.com
Exposures
COVID-19
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
January 29, 2024
Via
NewMediaWire
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
January 29, 2024
Via
TheNewswire.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 24, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
January 24, 2024
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
January 23, 2024
Via
InvestorPlace
GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
January 08, 2024
Via
NewMediaWire
GeoVax Announces Gedeptin Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
January 04, 2024
Via
NewMediaWire
GeoVax Announces Issuance of Malaria Vaccine Patent
January 03, 2024
Via
NewMediaWire
Topics
Intellectual Property
Exposures
Intellectual Property
GeoVax Labs And 2 Other Stocks Under $2 Insiders Are Buying
December 27, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox
December 19, 2023
Via
NewMediaWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.